SCYNEXIS, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 51
- Market Cap
- $56M
- Website
- http://www.scynexis.com
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05908682
- Locations
- 🇮🇳
AWINSA, New Delhi, Vasant Vihar, India
ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05668429
- Locations
- 🇬🇧
Quotient Sciences Limited, Nottingham, United Kingdom
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05399641
- Locations
- 🇺🇸
Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Wake (Mount Vernon Clinical Research), Atlanta, Georgia, United States
🇺🇸Women's Healthcare Research, San Diego, California, United States
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05178862
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇧🇪Saint Luc University Hospital, Brussels, Belgium
ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04307082
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04092725
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04092751
- Locations
- 🇦🇺
Scientia Clinical Research Limited Bright Building, Randwick, New South Wales, Australia
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
- Conditions
- Interventions
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT04029116
- Locations
- 🇺🇸
Chattanooga Medical Research Inc, Chattanooga, Tennessee, United States
🇺🇸Clinical Research Prime - ClinEdge - PPDS, Idaho Falls, Idaho, United States
🇺🇸Women's Healthcare Research Corp, San Diego, California, United States
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 455
- Registration Number
- NCT03987620
- Locations
- 🇺🇸
New Generation Medical Research, Hialeah, Florida, United States
🇺🇸Physician Care Clinical Research LLC, Sarasota, Florida, United States
🇺🇸Planned Parenthood Southeastern Pennsylvania The Elizabeth Blackwell Health Center, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT03734991
- Locations
- 🇺🇸
Women's Medical Research Group, Clearwater, Florida, United States
🇺🇸Unified Women's Clinical Research Greensboro, Greensboro, North Carolina, United States
🇺🇸Magnolia Ob/Gyn Research Center, LLC, Myrtle Beach, South Carolina, United States